Form 4: Mira Pharmaceuticals CFO Receives Incentive Stock Options
SEC Form 4
Michelle Yanez, CFO of Mira Pharmaceuticals, was granted incentive stock options to purchase 150,000 shares of common stock at an exercise price of $1.15.
Summary
- On March 26, 2024, Michelle Yanez, the Chief Financial Officer of Mira Pharmaceuticals, received incentive stock options.
- These options allow her to purchase 150,000 shares of the company's common stock at an exercise price of $1.15 per share.
- 50% of the options (75,000) will vest on September 26, 2024, and the remaining 50% will vest on March 26, 2025.
- Yanez also holds 57,799 stock options from previous grants with exercise prices of $5.00 and $6.50, which have various vesting dates.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and suggests confidence in the company's future performance. However, it also dilutes existing shareholders' equity.
Positives
- The granting of stock options to the CFO aligns her interests with those of the shareholders.
- The vesting schedule incentivizes the CFO to remain with the company for at least one year.
Industry Context
Granting stock options to executives is a common practice in the pharmaceutical industry to incentivize performance and align management's interests with those of shareholders. The size and terms of the grant are typical for a company of Mira Pharmaceuticals' size and stage.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
- Companies like BioNTech and Moderna also utilize stock options to incentivize their executives.
- The vesting schedules and exercise prices are generally in line with industry norms for similar-sized companies.
Stakeholder Impact
- Shareholders may experience slight dilution due to the potential issuance of new shares upon option exercise.
- Employees may be motivated by the executive team being incentivized to increase the share price.
- The company's creditors are unlikely to be impacted.
Key Dates
| Date | Description |
|---|---|
| June 15, 2022 | 3,334 stock options became exercisable at $5.00. |
| June 15, 2023 | 3,333 stock options became exercisable at $5.00. |
| April 28, 2023 | 15,566 stock options were issued at an exercise price of $6.50 each. |
| April 28, 2023 | 15,566 stock options were issued at an exercise price of $6.50 each. |
| August 17, 2023 | 20,000 stock options were issued at an exercise price of $6.50 each. |
| March 26, 2024 | Grant date of 150,000 incentive stock options at $1.15 exercise price. |
| September 26, 2024 | Vesting date for 50% (75,000) of the newly granted stock options. |
| March 26, 2025 | Vesting date for the remaining 50% (75,000) of the newly granted stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.